Press releases

Boston Scientific acquisition launches women's health focus on cancer and may lead to new diagnostic options for ovarian cancer.

Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor

U.K. court affirms that Edwards Lifesciences infringes Boston Scientific patent

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia

Data demonstrated RHYTHMIA™ Mapping System, paired with the INTELLAMAP ORION™ Mapping Catheter, safe and effective treatment for a variety of arrhythmias

Acquisition expands endoscopic portfolio to include radiofrequency devices

Boston Scientific announced its completed public offering of senior notes.

Boston Scientific announced the pricing of a public offering of senior notes.

"Our team delivered excellent fourth quarter and full year results, said chairman and CEO Mike Mahoney.

Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation

Randomized controlled trial demonstrates effectiveness of long-term treatment with sub-perception spinal cord stimulation

System offers non-opioid treatment option with multiple therapies for people with chronic pain

Based upon preliminary unaudited financial information, the company generated approximately $2.41 billion in sales during Q4 2017.

DBS platform offers physicians advanced technology to treat symptoms of Parkinson's disease

Company announces delay for commercialization of the LOTUS Edge™ Aortic Valve System in Europe and the U.S.

Boston Scientific will participate in the healthcare conference on December 7, 2017. A live webcast and replay will be available.

American Heart Association, American College of Cardiology and Heart Rhythm Society issue updated guidelines underscoring benefits of the S-ICD system

Late-breaking data presented at TCT 2017 with simultaneous publication in the Journal of the American College of Cardiology

“We continue to invest in a deep and innovative portfolio and expand into faster-growing markets," said CEO Mike Mahoney.

Acquisition to strengthen company's electrophysiology portfolio

HeartLogic is the first and only heart failure diagnostic in an implantable device shown to provide weeks of advance notice of an impending heart failure event.

Data presented demonstrate alert improves heart failure risk prediction

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

"Our strong financial performance in the first half of 2017 reflects our innovative portfolio,” said CEO Mike Mahoney.

Investor meeting will cover Boston Scientific’s business and long-term growth strategies, including by expanding category leadership and driving global growth.

Industry's first MR-conditional directional DBS System with stimulation visualization

Results from evaluation of real-world patients presented at American Thoracic Society International Conference

The first head-to-head pivotal study comparing two different TAVI platforms demonstrated the LOTUS™ Valve System’s superior efficacy.

BAcquisition expands company's structural heart portfolio; increases offerings for the treatment of patients with valvular heart disease

Largest prospective study of the WATCHMAN device presented as late-breaking trial at Heart Rhythm 2017

Analyses evaluated the impact of ethnicity, gender and income on cardiovascular outcomes

Late-breaker data presented at Heart Rhythm 2017

New devices combine longest-lasting battery technology, therapy optimization and HeartLogic™ heart failure diagnostics

"We are pleased with our performance in the first quarter,” said CEO Mike Mahoney

MADIT S-ICD trial to study EMBLEM™ MRI S-ICD System; part of pilot initiative to increase percentage of females enrolled in clinical studies

Acquisition will expand treatments for patients with valvular heart disease and strengthen company's position in structural heart globally

Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; potential for significant cost savings

Edwards found to infringe on Boston Scientific patents in Germany and U.K.

"Boston Scientific delivered excellent financial results in 2016,” said CEO Mike Mahoney

Acquisition will bring manufacturing assets and biologic tissue capabilities for use in Boston Scientific heart valve technologies.

$75M transaction enhances manufacturing expertise in structural heart

Acquisition expands Boston Scientific endoscopy portfolio with a comprehensive array of gastrointestinal services and devices

Boston Scientific today announced that its Cork, Ireland manufacturing facility has received the 2016 Shingo Prize for Excellence in Manufacturing from the Shingo Institute, part of the Jon M....

Boston Scientific (NYSE: BSX) today announced results from the first clinical trial evaluating the performance of the HeartLogic™ Heart Failure Diagnostic Service to predict impending heart...

Boston Scientific (NYSE: BSX) has acquired the gynecology and urology portfolio of Distal Access, LLC, a Salt Lake City based company that designs minimally invasive medical devices. The portfolio...

MARLBOROUGH, Mass., (Nov. 8, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the Dakota™ Nitinol Stone Retrieval Device with OpenSure™...

Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue...

Boston Scientific (NYSE: BSX) announced initial U.S. commercial performance results of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial...

As part of the commitment to support health equity for all patients, Boston Scientific Corporation (NYSE: BSX) sponsored the PLATINUM Diversity study to evaluate the clinical outcomes of the...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of $2.035 to...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Resolution 360™ Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled...

Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his...

Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...

Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain

CEO Mike Mahoney welcomes Fujimori as a business leader with “significant insights on how large companies plan, execute and compete globally.”

Studies show that treatment is less costly and has lower hospital re-admissions

Accelerates momentum to bring differentiated value to patients and health care systems

Full-body MRI access expands spinal cord stimulation offering and brings customized therapy to more patients suffering from chronic pain

Late-breaker data presented at HRS scientific sessions is most extensive post-market study for S-ICD

New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System

"This strong start enables us to raise our outlook for the year,” said Boston Scientific CEO Mike Mahoney

FDA approval includes ACCOLADE™ MRI and ESSENTIO™ MRI pacemakers and INGEVITY™ MRI pacing leads

European approval granted for third-generation system and all previously implanted, second-generation systems

Boston Scientific Corporation (NYSE: BSX) today announced the launch of the AXIOS™ Stent and Electrocautery Enhanced Delivery System to help physicians manage two serious complications from...

Two organizations to share intellectual property and stimulate the rapid development of medical devices to address unmet clinical needs

FDA approval granted on the heels of CE Mark for the IntellaTip MiFi™ open-irrigated catheter

ACUITY™ X4 Quadripolar Left Ventricular Leads to be used in trial pursuing MRI labeling for cardiac defibrillation and resynchronization systems

First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe

CMS will cover percutaneous LAAC therapy for Medicare beneficiaries consistent with the FDA label when specific conditions are met

"Our accomplishments in 2015 demonstrate our continued momentum,” said Boston Scientific CEO Mike Mahoney

Bronchial thermoplasty (BT) delivered by the ALAIR™ System offers proven reduction in asthma attacks for adults with severe asthma not well controlled with medication

Care Pathway Transformation solution is designed to enable providers to make better-informed decisions based on patient population insights

Single-use system for stone removal eliminates maintenance, reprocessing and sterilization

Study demonstrates spinal cord stimulation device provided significant decrease in average pain scores sustained over a two-year period

Catheter used to treat deep vein thrombosis to be commercialized in U.S. and Europe

First implants occur in Europe, commencing limited market release

For the second consecutive year, Boston Scientific is named one of the "Best Places to Work for LGBT Equality"

Transaction to expand interventional oncology portfolio with drug-eluting microspheres and spherical embolics

"Our excellent third quarter performance was driven by strong sales and differentiated adjusted operating margin expansion," said CEO Mike Mahoney

Investment continues alliance for percutaneous mitral valve replacement established in 2012

Up to $25,000 in prizes to be awarded to winners

New category of drug-eluting stent approved for U.S. patients

Provides minimally invasive alternative to an esophagectomy

MAJESTIC trial data support strong safety profile with low target lesion revascularization rate

System includes first directional lead with current steering and expanded programming flexibility

Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systems

U.S. launch underway for therapy designed to treat Peripheral Artery Disease

Men’s health and prostate health acquisition positions Boston Scientific as a urology leader

Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions

"Our strong performance in the second quarter reflects the consistent execution of our global teams," said Mike Mahoney, CEO of Boston Scientific.

First guidewire designed specifically for TAVI/R now sized for smaller ventricles

First Patients Enrolled in the FAST Feasibility Study

Demonstrates growing clinical acceptance for novel, procedure-based treatment option for severe asthma

Study to evaluate patients implanted with S-ICD for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function

Spinal cord stimulator (SCS) system provided 1.5x better overall pain relief and 2x better low back pain relief than previous generation system

World's smallest 16-contact high-capacity primary cell device expands spinal cord stimulator system (SCS) offering

Compelling results presented at EuroPCR 2015 add to growing body of evidence supporting performance and safety